60 Degrees’ Arakoda Gets US FDA Panel Nod For Malaria Prophylaxis

Postmarketing studies are needed to assess tafenoquine’s efficacy in children, older adults and heavier individuals, and to answer questions about psychiatric safety and other adverse events, advisory committee says.

FDA Advisory Committee Feature image

A US FDA advisory committee endorsed the efficacy and safety of [60 Degrees Pharmaceuticals LLC]’s Arakoda (tafenoquine) for malaria prevention in adults but is counting on postmarketing studies to provide clarity on questions left unanswered by the “patchwork” of small trials supporting the application.

Additional studies are needed after approval to assess efficacy in adults over age 65 years, pediatric populations and heavier individuals,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers